{
    "clinical_study": {
        "@rank": "80823", 
        "brief_summary": {
            "textblock": "To estimate the response rate, response duration, clinical benefit, and toxicity of\n      mitoguazone dihydrochloride (MGBG) in patients with AIDS-related refractory or relapsing\n      non-Hodgkin's lymphoma (NHL)."
        }, 
        "brief_title": "A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma", 
        "condition": [
            "Lymphoma, Non-Hodgkin", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive infusions of MGBG on days 1 and 8 and every 2 weeks thereafter. It is\n      suggested that a lumbar puncture be performed to evaluate for leptomeningeal disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV positivity by ELISA confirmed by Western blot.\n\n          -  AIDS-related NHL that is refractory or relapsed.\n\n          -  Life expectancy of at least 12 weeks.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Concomitant malignancy OTHER THAN curatively treated carcinoma in situ of the cervix;\n             basal or squamous cell carcinoma of the skin; or non-active, non-visceral Kaposi's\n             sarcoma not requiring active chemotherapy.\n\n          -  Active uncontrolled bacterial infection, viral infection (other than herpes simplex),\n             or fungal infection (other than oropharyngeal candidiasis) that requires treatment\n             within 2 weeks of study entry.\n\n          -  Significant cardiovascular disease.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Hormonal therapy (except medications given for muscle wasting, such as testosterone\n             or Megace).\n\n          -  Other chemotherapy.\n\n          -  Investigational anti-cancer drugs.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Concomitant radiation to sites other than CNS.\n\n        Patients with the following prior conditions are excluded:\n\n        Prior malignancy OTHER THAN curatively treated carcinoma in situ of the cervix; basal or\n        squamous cell carcinoma of the skin; or non-active, non-visceral Kaposi's sarcoma not\n        requiring active chemotherapy.\n\n        Recommended:\n\n          -  Prophylaxis for PCP and oral candidiasis.\n\n        Required in patients with leptomeningeal disease:\n\n          -  Intrathecal methotrexate or cytarabine (Ara-C).\n\n          -  Leucovorin.\n\n        Required in patients with leptomeningeal disease:\n\n        Cranial radiation to a helmet field."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002348", 
            "org_study_id": "241A", 
            "secondary_id": "IDD-007"
        }, 
        "intervention": {
            "intervention_name": "Mitoguazone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Mitoguazone"
        }, 
        "keyword": [
            "Lymphoma, Non-Hodgkin", 
            "Acquired Immunodeficiency Syndrome", 
            "Lymphoma, AIDS-Related", 
            "Mitoguazone"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "782453217"
                }, 
                "name": "ILEX Oncology Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma Associated With Acquired Immunodeficiency Syndrome", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "PMID": "9060550", 
            "citation": "Levine AM, Tulpule A, Tessman D, Kaplan L, Giles F, Luskey BD, Scadden DT, Northfelt DW, Silverberg I, Wernz J, Espina B, Von Hoff D. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. J Clin Oncol. 1997 Mar;15(3):1094-103."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002348"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1996"
    }, 
    "geocoordinates": {
        "ILEX Oncology Inc": "29.424 -98.494"
    }
}